Novel 3-D Computer Model Can Help Predict Pathogens’ Roles in Cancer

Figure with an example of the team's 3-D modeling approach

To understand how bacterial and viral infections contribute to human cancers, four NCI at Frederick scientists turned not to the lab bench, but to a computer. The team has created the world’s first—and currently, only—3-D computational approach for studying interactions between pathogen proteins and human proteins based on a molecular adaptation known as interface mimicry.


Frederick National Laboratory Advisory Committee Welcomes New FNL, NCI Leaders

Dr. Doug Lowy, former acting NCI director, speaks at a Frederick National Laboratory Advisory Committee meeting.

The Frederick National Laboratory Advisory Committee recently met to discuss the future of several high-profile Frederick National Lab initiatives in a meeting that included a chance to meet the new NCI and FNLCR leaders. Here is a look at a few of the highlights from the last of the 2017 FNLAC meetings.


Second RAS Symposium Brings Together World’s Leading RAS Scientists

Photo of day one of the Second RAS Symposium

From December 6–8, the Advanced Technology Research Facility of the Frederick National Laboratory for Cancer Research was abuzz with conversation and collaboration as nearly 450 scientists, academics, and industry partners gathered for the Second RAS Initiative Symposium. Attendees hailed from 14 nations, dozens of institutions, and diverse scientific backgrounds, but they shared a common purpose: to present and discuss their research on RAS genes and cancer.


NCI Helps Children’s Hospital of Philadelphia to Identify and Treat New Target in Pediatric Cancer

Artist's depiction of the antibody-drug conjugate bound to GPC2

There may be a new, more effective method for treating high-risk neuroblastoma, according to scientists at the Children’s Hospital of Philadelphia and collaborators in the Cancer and Inflammation Program at NCI at Frederick. Together, the groups published a study describing a previously unrecognized protein on neuroblastoma cells, called GPC2, as well as the creation of a novel antibody-drug conjugate, a combination of a human antibody and a naturally occurring anticancer drug, that locates and binds to GPC2 in a highly efficient way.



Subscribe to Science